Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer Growth

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2009 Apr 2

PMID 19337234

Citations 19

Authors

Sarfraz Ahmad

Garrett Casey

Paul Sweeney

Mark Tangney

Gerald C OSullivan

Affiliations

Soon will be listed here.

Abstract

Prostate stem cell antigen (PSCA) is a cell surface antigen expressed in normal human prostate and over expressed in prostate cancer. Elevated levels of PSCA protein in prostate cancer correlate with increased tumor stage/grade, with androgen independence and have higher expression in bone metastases. In this study, the PSCA gene was isolated from the transgenic adenocarcinoma mouse prostate cell line (TRAMPC1), and a vaccine plasmid construct was generated. This plasmid PSCA (pmPSCA) was delivered by intramuscular electroporation (EP) and induced effective antitumor immune responses against subcutaneous TRAMPC1 tumors in male C57 BL/6 mice. The pmPSCA vaccination inhibited tumor growth, resulting in cure or prolongation in survival. Similarly, the vaccine inhibited metastases in PSCA expressing B16 F10 tumors. There was activation of Th-1 type immunity against PSCA, indicating the breaking of tolerance to a self-antigen. This immunity was tumor specific and was transferable by adoptive transfer of splenocytes. The mice remained healthy and there was no evidence of collateral autoimmune responses in normal tissues. EP-assisted delivery of the pmPSCA evoked strong specific responses and could, in neoadjuvant or adjuvant settings, provide a safe and effective immune control of prostate cancer, given that there is significant homology between human and mouse PSCA.

Citing Articles

Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.

Nayerpour Dizaj T, Doustmihan A, Sadeghzadeh Oskouei B, Akbari M, Jaymand M, Mazloomi M Cancer Cell Int. 2024; 24(1):135.

PMID: 38627732 PMC: 11020972. DOI: 10.1186/s12935-024-03320-6.

Electroporation-Based Treatments in Urology.

Kielbik A, Szlasa W, Saczko J, Kulbacka J Cancers (Basel). 2020; 12(8).

PMID: 32784598 PMC: 7465806. DOI: 10.3390/cancers12082208.

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.

Link T, Kuithan F, Ehninger A, Kuhlmann J, Kramer M, Werner A Oncotarget. 2017; 8(33):54592-54603.

PMID: 28903367 PMC: 5589606. DOI: 10.18632/oncotarget.17523.

Intratumoural production of TNFα by bacteria mediates cancer therapy.

Murphy C, Rettedal E, Lehouritis P, Devoy C, Tangney M PLoS One. 2017; 12(6):e0180034.

PMID: 28662099 PMC: 5491124. DOI: 10.1371/journal.pone.0180034.

Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.

Mai T, Ma R, Li Z, Bi S Braz J Med Biol Res. 2016; 49(11):e5620.

PMID: 27783810 PMC: 5089234. DOI: 10.1590/1414-431X20165620.

References

KELALIS P, Greene L, HARRISON Jr E . Granulomatous prostatitis. A mimic of carcinoma of the prostate. JAMA. 1965; 191(4):287-9. DOI: 10.1001/jama.191.4.287. View

GROSSMANN M, Wood M, Celis E . Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J Urol. 2002; 19(5):365-70. DOI: 10.1007/pl00007104. View

Hodge J, Grosenbach D, Aarts W, Poole D, Schlom J . Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003; 9(5):1837-49. View

Rosenberg S . Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997; 18(4):175-82. DOI: 10.1016/s0167-5699(97)84664-6. View

Mosmann T, Coffman R . TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7:145-73. DOI: 10.1146/annurev.iy.07.040189.001045. View

Elkord E . Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(3):224-36. DOI: 10.1038/sj.pcan.4500964. View

Ulmer J, Wahren B, Liu M . Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006; 12(5):216-22. DOI: 10.1016/j.molmed.2006.03.007. View

Gu Z, Thomas G, Yamashiro J, Shintaku I, dOrey F, Raitano A . Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000; 19(10):1288-96. DOI: 10.1038/sj.onc.1203426. View

Reiter R, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E . Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998; 95(4):1735-40. PMC: 19171. DOI: 10.1073/pnas.95.4.1735. View

10.

Hojman P, Gissel H, Andre F, Cournil-Henrionnet C, Eriksen J, Gehl J . Physiological effects of high- and low-voltage pulse combinations for gene electrotransfer in muscle. Hum Gene Ther. 2009; 19(11):1249-60. DOI: 10.1089/hum.2008.059. View

11.

Soden D, Larkin J, Collins C, Tangney M, Aarons S, Piggott J . Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett. 2005; 232(2):300-10. DOI: 10.1016/j.canlet.2005.03.057. View

12.

Dannull J, Diener P, Prikler L, Furstenberger G, Cerny T, Schmid U . Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000; 60(19):5522-8. View

13.

Aragon-Ching J, Williams K, Gulley J . Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007; 12:4957-71. DOI: 10.2741/2441. View

14.

Gurunathan S, Klinman D, Seder R . DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000; 18:927-74. DOI: 10.1146/annurev.immunol.18.1.927. View

15.

Nesslinger N, Sahota R, Stone B, Johnson K, Chima N, King C . Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 2007; 13(5):1493-502. DOI: 10.1158/1078-0432.CCR-06-1772. View

16.

Vesalainen S, Lipponen P, Talja M, Syrjanen K . Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 1994; 30A(12):1797-803. DOI: 10.1016/0959-8049(94)e0159-2. View

17.

Schirmbeck R, Reimann J . Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Biol Chem. 2001; 382(4):543-52. DOI: 10.1515/BC.2001.068. View

18.

Sanda M, Restifo N, Walsh J, Kawakami Y, Nelson W, Pardoll D . Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 1995; 87(4):280-5. PMC: 2104544. DOI: 10.1093/jnci/87.4.280. View

19.

Foldvari M, Babiuk S, Badea I . DNA delivery for vaccination and therapeutics through the skin. Curr Drug Deliv. 2006; 3(1):17-28. DOI: 10.2174/156720106775197493. View

20.

DeglInnocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio M . Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res. 2008; 68(1):292-300. DOI: 10.1158/0008-5472.CAN-07-2429. View